Ross手术较机械瓣膜为成人提供生存获益:一项倾向匹配的全国性分析
该回顾性分析基于捷克共和国国家心脏手术登记处前瞻性记录的数据,采用倾向评分匹配比较2009年至2020年间在两个专门中心行Ross手术的患者与全国所有行机械主动脉瓣置换术(mAVR)的患者。共匹配291对,Ross组全因死亡率低于mAVR组(0.7% vs 6.5%,P=0.015),再手术风险无差异(4.5% vs 5.5%,P=0.66)。结论认为Ross手术应作为专门中心年轻和中年主动脉瓣疾病患者的首选治疗。
要点
- 倾向匹配后Ross组全因死亡率0.7%低于mAVR组6.5%(P=0.015)。
- 仅计入心脏和瓣膜相关死亡时,Ross组生存获益仍显著(P=0.048)。
- 两组再手术风险无差异(4.5% vs 5.5%,P=0.66)。
核心结论
- Ross手术较mAVR提供显著的 midterm 生存获益,围术期并发症风险相当,mAVR术后患者生存率降低,因此Ross手术应作为专门中心年轻和中年主动脉瓣疾病患者的首选治疗。
研究设计与样本
- 本研究为回顾性分析,数据来自捷克共和国国家心脏手术登记处的前瞻性记录,采用倾向评分匹配比较2009年至2020年间在两个专门中心行Ross手术的成人患者与全国所有行mAVR的患者。
主要发现
- 研究期间296名成人行Ross手术,5120例行mAVR,匹配后比较291对。
- 两组均无院内死亡,围术期并发症风险相似。
- 平均随访时间Ross组4.1年 vs mAVR组6.1年,Ross组全因死亡率0.7% vs mAVR组6.5%(P=0.015)。
- 仅计入心脏和瓣膜相关死亡时,Ross组生存获益仍显著(P=0.048)。
- mAVR组相对生存率较年龄和性别匹配的一般人群显著降低,Ross组无此现象;再手术风险两组无差异(4.5% vs 5.5%,P=0.66)。
临床怎么用
- 作者认为,对于年轻和中年主动脉瓣疾病患者,在专门中心应优先选择Ross手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The choice of optimal surgical treatment for young and middle-aged adults with aortic valve disease remains a challenge. Mechanical aortic valve replacement (mAVR) is generally preferred despite promising recent outcomes of the Ross procedure. Our goal was to compare the strategies at a nationwide level. METHODS: This study was a retrospective analysis of prospectively recorded data from the National Registry of Cardiac Surgery of the Czech Republic. Using propensity score matching, we compared the outcomes of patients undergoing the Ross procedure in 2 dedicated centres with all mAVRs performed in country between 2009 and 2020. RESULTS: Throughout the study period, 296 adults underwent the Ross procedure and 5120 had an mAVR. We found and compared 291 matched pairs. There were no in-hospital deaths, and the risk of perioperative complications was similar in both groups. Over the average follow-up period of 4.1 vs 6.1 years, the Ross group had a lower all-cause mortality (0.7 vs 6.5%; P = 0.015). This result remained significant even when accounting for cardiac- and valve-related deaths only (P = 0.048). Unlike the Ross group, the mAVR group had a significantly lower relative survival compared with the age- and sex-matched general population. There was no difference in the risk of reoperation (4.5 vs 5.5%; P = 0.66). CONCLUSIONS: The Ross procedure offers a significant midterm survival benefit over mAVR. The procedures have a comparable risk of perioperative complications. Patients after mAVR have reduced survival. Thus, the Ross procedure should be the preferred treatment option for young and middle-aged adults with aortic valve disease in dedicated centres.
引用
- Gofus J, Fila P, Drabkova S, et al. Ross procedure provides survival benefit over mechanical valve in adults: a propensity-matched nationwide analysis. Eur J Cardiothorac Surg. 2022. PMID: 35150238. doi:10.1093/ejcts/ezac013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。